The global hepatitis therapeutics market is expected to reach
USD 25.8 billion by 2025 according to a new report by Grand View Research, Inc.
Few factors that are expected to drive the market over the forecast period
include rising number of hepatitis infected population, growing consumption of
alcohol & drugs, and improving accessibility to hepatitis drugs.
Based on the duration for which the patient
suffers, viral hepatitis is generally categorized into two types. If the
condition lasts for less than six months, then it is classified as acute, when
the condition persists for more than six months, then it is a case of chronic
hepatitis. People with HIV infection & HCV-infected sexual partners,
recipients of infected blood, patients who inject drugs & use intranasal
drugs, and population groups who live in unhygienic conditions are at high risk
of hepatitis.
Based on the estimates of WHO, approximately
400 million people are infected with at least one form of hepatitis globally
and annually nearly 1.4 people die due to the condition. In order to prevent
hepatitis, few government and private agencies are actively involved in the
vaccination drive to prevent hepatitis. As compared to hepatitis A and B, HCV
leads to more serious complications. According to the estimates of WHO,
globally annually 150 million are impacted by hepatitis C infection. Moreover,
majority of HCV infected patients develop liver cancer or liver cirrhosis and
nearly 700,000 people die due to hepatitis C infection & associated
conditions.
Browse full research report on Hepatitis
Therapeutics Market:
https://www.grandviewresearch.com/industry-analysis/hepatitis-therapeutics-market
Further Key
Findings From the Report Suggest:
- Owing to high prevalence of target disease
with subsequently surge in treatment rate HCV, thus hepatitis C
therapeutics held the majority market share in 2016
- In 2016, North American region accounted for
majority of revenue share of 42.9% owing to high patient awareness levels
and the presence of advanced healthcare infrastructure
- However, Asia Pacific is anticipated to
witness the maximum growth with a CAGR of 5.8% over the forecast period
owing to rapidly increasing healthcare expenditure
- Key players include Gilead, Johnson &
Johnson, Merck & Co. Inc., Bristol-Myers Squibb Company, and AbbVie
Inc.
Browse request sample of this report by
Grand View Research: https://www.grandviewresearch.com/industry-analysis/hepatitis-therapeutics-market/request/rs1
Grand
View Research has segmented the global hepatitis therapeutics market report on
the disease type, and region:
Disease Type
Outlook (Revenue, USD Million, 2014 - 2025)
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Others
Regional
Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- Mexico
- Middle East &
Africa
- South Africa
About Grand View Research
Grand View Research, Inc. is a U.S. based market
research and consulting company, registered in the State of California and
headquartered in San Francisco. The company provides syndicated research
reports, customized research reports, and consulting services. To help clients
make informed business decisions, we offer market intelligence studies ensuring
relevant and fact-based research across a range of industries, from technology
to chemicals, materials and healthcare.
No comments:
Post a Comment